Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer

Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions: Drug: modified FOLFIRINOX; Drug: Pentamidine 300 MG Injection

Sponsors: University of Oklahoma

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 19, 2026Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments